However, Li and colleagues analyzed data from 7893 patients and found that TP53 mutations were only prognostically relevant in 9 cancer types in the TCGA dataset including lung adenocarcinoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, acute myeloid leukemia (AML) and clear cell renal carcinoma [18]. Here, TP53 is linked to acute myeloid leukemia.